Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions

a topical therapy and migraine technology, applied in the field of migraine treatment, can solve the problems of frequent disruption of an individual's daily life, affecting function, sickness and vomiting, etc., and achieve the effects of avoiding discomfort and risks of intravenous treatment, avoiding side effects, and increasing efficiency

Inactive Publication Date: 2007-03-22
AFGIN PHARMA
View PDF56 Cites 73 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0071] Sickness and vomiting typically occurring in migraine make oral administration of the active agent(s) for migraine treatment difficult. Therefore, topical administration of an active agent(s) may offer considerable advantages.
[0072] Certain other advantages of topical administration may include increased efficiency by avoiding the first-pass effect of the liver, avoiding discomfort and risks of an intravenous treatment, avoiding side effects in the region of the gastrointestinal tract in the case of oral medication, and good patient acceptance. Absorption peaks involving the risk of systemic side effects may also be avoided.
[0073] Typically the site of administration of transdermal delivery

Problems solved by technology

Frequently, migraine is accompanied by sickness and vomiting and a sensitivity to light and noise.
Muscle sprains, muscle spasms, spasticity, tension headaches and tension-related migraines are also common debilitating conditions that are associated with acute pain, chronic pain and involuntary movement that can be so severe that the condition(s) frequently disrupt an individual's daily life.
The result is chronic, severe spasm of the muscles of the extremities hindering function and causing pain.
All of these compounds, however, have some adverse effects whic

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of Tizanidine Transdermal Gel

[0147] Tizanidine transdermal gel was prepared by chemically extracting tizanidine from commercially available tablets and mixing the extracted tizanidine with a transdermal compounding medium, e.g., Lipoderm® to obtain a topical gel formulation containing 2 mg / ml of tizanidine. The tizanidine gel was placed into tuberculin syringes for administration.

Treatment Methods

[0148] Initial doses of 0.4 mg to 0.8 mg of tizanidine were administered with additional applications made after 15-30 minutes, up to a total of 4.0 mg tizanidine, as necessary in certain severe cases. The transdermal gel was applied by gentle rubbing of the gel into the effected muscle(s) using a gloved finger. In cases of spasticity, equal amounts of gel were applied to the extensor and flexor muscles involved.

[0149] Twenty-three (23) patients with a variety of clinically significant conditions of muscle spasms and spasticity were treated in an open-label study. The pati...

example 3

Ergot Alkaloid Transdermal Gel

Preparation of Methysergide Transdermal Gel

[0155] Methysergide transdermal gel is prepared by chemically extracting methysergide from commercially available tablets and mixing the extracted methysergide with a transdermal compounding medium, e.g., Lipoderm® to obtain a topical gel formulation containing methysergide 2 mg / ml. The methysergide gel is placed into tuberculin syringes for administration.

examples 4-6

Sumatriptan / Additional Active Agent Transdermal Gel

[0156] A combination sumatriptan / additional active agent gel was produced with the formula set forth in Table 2 below:

TABLE 2IngredientAmt / unit (mg)Imitrex ® (sumatriptan succinate)2200 mg (22 tablets)100 mg tabletAdditional Active* mg (** tablets)Ethoxy Diglycol Liquid2.200 gmLecithin / Isopropyl Palmitate4.400 gm50 / 50 gelPluronic F127 20% Liquid11.286 gm 

* See below for mg quantities of additional active agents

** See below for tablet amounts of additional active agents

Dosage forms of the above formulation were prepared according to the following procedure: [0157] 1. 100 mg Imitrex® tablets (sumatriptan succinate) and the requisite amount of additional active agent tablets are crushed and mixed with Lecithin / Isopropyl Palmitate 50 / 50 gel. [0158] 2. Thereafter, the Ethoxy diglycol liquid is added and mixed together with 1. [0159] 3. The pluronic F127 20% is also added to the mixture. [0160] 4. The resultant formulation is put th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to view more

Abstract

The invention is directed to topical formulations and methods of treating a migraines and/or cluster headaches, muscle sprains, muscle spasms, spasticity, tension headaches, tension related migraines and related conditions associated with muscle tension and pain with a therapeutically effective amount of an ergot alkaloid, skeletal muscle relaxant, serotonin agonist, combinations thereof, pharmaceutically acceptable salt thereof, prodrugs thereof or derivative thereof.

Description

BACKGROUND OF THE INVENTION [0001] The present invention is directed to methods and formulations for treating migraines, muscle sprains, muscle spasms, spasticity, tension headache, tension-related migraines and related conditions associated with muscle tension and pain. [0002] Migraine headaches are a debilitating condition in which some 53 million persons per year suffer acute pain. Frequently, migraine is accompanied by sickness and vomiting and a sensitivity to light and noise. [0003] Several theories on the pathogenesis of migraine have been hypothesized and include: i) the vascular theory (i.e., migraine is a vasospastic disorder that is initiated by vasoconstriction in the cranial vasculature); ii) the cortical spreading depression theory (i.e., CSD begins with a brief wave of excitation, followed by a prolonged period of neuronal depression, which is associated with disturbances in nerve cell metabolism and regional reductions in blood flow); iii) the neurovascular hypothesi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/08A61K31/551A61K31/48A61K31/498A61K31/445A61F13/02A61KA61K31/455A61K31/55
CPCA61K9/0014A61K31/433A61K31/445A61K31/455A61K31/48A61K31/498A61K31/55A61K31/551A61K45/06A61K47/10A61K47/14A61K47/24A61K47/44A61K9/06A61K31/4045A61K2300/00A61P21/00A61P21/02A61P25/06
Inventor AUNG-DIN, RONALD
Owner AFGIN PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap